When a biotech company set out to evaluate the potential of the alpha-mitter Lead-212 for targeting a widely expressed oncology marker, they faced two key challenges: a gap in applicable experience, and no internal radiochemistry or targeted-radiotherapy platform. This case study outlines how we were able to help this biotech access the radiopharmaceutical field by developing an end-to-end roadmap, from ligand selection and chelation through in vivo proof-of-concept, turn a high-risk, ambitious idea into a structured development program backed by meaningful data.
